WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP ...
The success of virtual GMP inspections performed during the pandemic may lead to more flexible opportunities in the future. A temporary system, under which good manufacturing practice (GMP) ...
It is very important for pharmaceutical companies to plan carefully for all Good Manufacturing Practice (GMP) inspections, as a successful outcome is required for continued operations. Careful ...
WUXI, China, April 6, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully ...
WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing ...
SHANGHAI, China, Feb. 23 /PRNewswire-Asia/ -- WuXi PharmaTech ( WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China ...
Indian medical device manufacturers are enhancing their Good Manufacturing Practice (GMP) compliance, reinforcing India's role as a trusted global supplier in the healthcare and MedTech sectors. This ...
PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced ...
HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results